Department of Medical Sciences, Dermatology and Venereology, Uppsala University, Uppsala, Sweden.
Clin Auton Res. 2015 Jun;25(3):161-7. doi: 10.1007/s10286-015-0278-x. Epub 2015 Mar 14.
Compensatory hyperhidrosis (CH) is the most common adverse complication of sympathectomy. It often has a major negative impact on life quality. No efficient treatment of CH is available. We report nine cases of CH after sympathectomy, which were treated with botulinum toxin A/B (BTX) and anticholinergics.
The patients responded to a dermatology life quality index (DLQI) questionnaire before injections with BTX and 3 weeks after treatment. At the follow-up visit, the participants also ranked the effect of the treatment on a five-grade scale. Three patients had residual sweating after BTX treatment, and received additional anticholinergics at the follow-up visit. Those subjects eventually had a third evaluation with the DLQI.
The DLQI score was, on average, 16.4 before treatment and decreased to 4.8 after BTX injections. Eight out of nine patients were satisfied with the treatment. The average DLQI score decreased to 2.2 when the patients with residual sweating (n = 3) received additional anticholinergics. Adverse events from BTX were mild and temporary, but dry mouth was substantial in one patient using anticholinergics.
A combination of BTX A/B and anticholinergics alleviated the hyperhidrosis with minor side-effects. We consider this treatment safe, effective, and well tolerated.
代偿性多汗症(CH)是交感神经切断术后最常见的不良反应。它常对生活质量产生重大负面影响。目前尚无有效的 CH 治疗方法。我们报告了 9 例交感神经切断术后 CH 患者,他们接受了肉毒毒素 A/B(BTX)和抗胆碱能药物治疗。
患者在接受 BTX 注射前和治疗后 3 周回答皮肤病生活质量指数(DLQI)问卷。在随访时,参与者还对治疗效果进行了五级评分。3 例患者在 BTX 治疗后仍有出汗,在随访时接受了额外的抗胆碱能药物治疗。这些患者最终接受了第三次 DLQI 评估。
治疗前的 DLQI 平均得分为 16.4,治疗后降至 4.8。9 例患者中有 8 例对治疗满意。接受额外抗胆碱能药物治疗的 3 例仍有出汗的患者的平均 DLQI 评分降至 2.2。BTX 的不良反应轻微且短暂,但 1 例使用抗胆碱能药物的患者出现口干。
BTX A/B 和抗胆碱能药物的联合治疗缓解了多汗症,副作用较小。我们认为这种治疗安全、有效且耐受性良好。